Ofev Safely Slows Lung Function Decline in SSc-ILD, Long-Term Study Finding

Ofev Safely Slows Lung Function Decline in SSc-ILD, Long-Term Study Finding

294490

Ofev Safely Slows Lung Function Decline in SSc-ILD, Long-Term Study Finding

Ofev (nintedanib) safely and effectively slowed lung function decline in people with interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD), according to an interim analysis of the ongoing and long-term SENSCIS-ON study. “The SENSCIS-ON trial provides important new evidence about the longer-term use of nintedanib [Ofev] in people living with SSc-ILD, showing a sustained reduction in lung function decline with a manageable safety profile,” Kristin B. Highland, MD, a lead author of the SENSCIS-ON study, said in…

You must be logged in to read/download the full post.